Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
11.66
-0.34 (-2.83%)
Feb 21, 2025, 4:00 PM EST - Market closed
Bicycle Therapeutics Revenue
Bicycle Therapeutics had revenue of $2.68M in the quarter ending September 30, 2024, a decrease of -50.00%. This brings the company's revenue in the last twelve months to $36.90M, up 48.60% year-over-year. In the year 2023, Bicycle Therapeutics had annual revenue of $26.98M with 86.52% growth.
Revenue (ttm)
$36.90M
Revenue Growth
+48.60%
P/S Ratio
16.29
Revenue / Employee
$129,923
Employees
284
Market Cap
805.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BCYC News
- 17 days ago - Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 19 days ago - Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data - Seeking Alpha
- 5 weeks ago - Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones - Business Wire
- 6 weeks ago - Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification - Business Wire
- 2 months ago - Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts - Business Wire
- 3 months ago - Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update - Business Wire